Pharmacology/Pharmaceutical Industry | Page 31 of 165 | Links Medicus Content Curation & Alerts in Medicine

M-A: Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis.

2 Feb, 2022 | 08:20h | UTC

Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis – The Lancet Gastroenterology & Hepatology (link to abstract – $ for full-text)

Commentary: Review finds upadacitinib most effective for moderate to severe ulcerative colitis remission – ACP Gastroenterology

Observational study suggests Ceftaroline has comparable efficacy vs. Daptomycin for the treatment of Methicillin-Resistant Staphylococcus aureus bloodstream infection.

2 Feb, 2022 | 08:07h | UTC

Multicenter Cohort Study of Ceftaroline versus Daptomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infection – Open Forum Infectious Diseases

Commentary on Twitter

New in OFID: A multicenter retrospective observational cohort study found no difference in treatment failure or mortality between MRSA bloodstream infections treated with ceftaroline or daptomycin.

?: https://t.co/3QB5JXd8s5 @PaulSaxMD @DrJLi @FungalDoc @IDpharmresearch pic.twitter.com/zNa9XRWP8F

— IDSA (@IDSAInfo) December 29, 2021

Observational study: Pharmacist involvement in the care of critically ill patients may reduce resource utilization, adverse drug events, and medical costs.

1 Feb, 2022 | 09:47h | UTC

PHarmacist Avoidance or Reductions in Medical Costs in CRITically Ill Adults: PHARM-CRIT Study – Critical Care Explorations

Commentary from the author on Twitter (thread – click for more)

PHARM-CRIT Study
?‍? 215 ICU PharmDs at 85 centers
?55,926 accepted interventions on 27,681 patients over 3,148 shifts
?$23,404,089 cost avoidance; monetary benefit-to-cost ratio for ICU pharmacists $3.3:1 – $9.6:1@SCCM_CPP @SCCM #TwitteRx #PharmICU https://t.co/Hv4jPwU6eb

— Megan Rech, PharmD, MS (@MeganARech) December 16, 2021

Does the world need an Omicron vaccine? What researchers say.

1 Feb, 2022 | 08:53h | UTC

Does the world need an Omicron vaccine? What researchers say – Nature

M-A: Vasopressin and glucocorticoids for in-hospital cardiac arrest.

1 Feb, 2022 | 08:43h | UTC

Vasopressin and glucocorticoids for in-hospital cardiac arrest: A systematic review and meta-analysis of individual participant data – Resuscitation

Commentary on Twitter

Systemic review and meta analysis post VAM-IHCA.
▶️ Moderate certainty for benefit with steroids and vasopressin on ROSC
▶️ Less certainty for longer term outcomes @mathiasholmb @LarsWAndersen1 @AsgerGranfeldt https://t.co/K3jZ1gBs1h

— Critical Care Reviews (@CritCareReviews) January 4, 2022

The extraordinary success of Covid-19 vaccines, in two charts.

1 Feb, 2022 | 08:48h | UTC

The extraordinary success of Covid-19 vaccines, in two charts – Vox

RCT: In patients with rheumatoid arthritis, treatment with oral drug Tofacitinib increases cardiovascular and cancer risk compared to treatment with subcutaneous TNF inhibitors.

1 Feb, 2022 | 08:35h | UTC

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis – New England Journal of Medicine (link to abstract – $ for full-text)

Video: CV and Cancer Risk with Tofacitinib in RA – New England Journal of Medicine

Commentary: CV, Cancer Risk Up With Tofacitinib for Rheumatoid Arthritis – HealthDay

RCT: Sugemalimab improves progression-free survival vs. placebo in patients with metastatic non-small-cell lung cancer.

1 Feb, 2022 | 08:25h | UTC

Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial – The Lancet Oncology (link to abstract – $ for full-text)

Commentaries:

Sugemalimab shows promise for locally advanced, metastatic NSCLC – Medicine Matters

Sugemalimab Boosts Outcomes in NSCLC – MedPage Today (free registration required)

Commentary on Twitter

In the phase III GEMSTONE-302 trial of chemo + sugemalimab or placebo in 479 with untreated advanced-stage NSCLC, mPFS was 9.0 vs 4.9 months (HR 0.48; P<0.0001); OS was 72.4% vs 62.0% at 12 months & 47.1% vs 38.1% at 24 months (HR 0.67, 95% CI 0.50–0.90): https://t.co/z6f00tqy8B

— NatureRevClinOncol (@NatRevClinOncol) January 19, 2022

Meta-analysis: Androgen deprivation therapy, in addition to radiotherapy, is associated with improved metastasis-free survival in men with localized prostate cancer.

1 Feb, 2022 | 08:24h | UTC

Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis – The Lancet Oncology (link to abstract – $ for full-text)

Commentary: Effect of ADT Use and Duration in Combination With Definitive Radiotherapy for Localized Prostate Cancer – The ASCO Post

Registry study in Denmark found an increased bleeding risk with the association of systemic Fluconazole and Apixaban (OR 3.5; 95% CI, 1.4-10.6).

1 Feb, 2022 | 08:13h | UTC

Bleeding Risk Following Systemic Fluconazole or Topical Azoles in Patients with Atrial Fibrillation on Apixaban, Rivaroxaban, or Dabigatran – American Journal of Medicine

Observational analysis in Lombardy, Italy, showed a gradual decrease in protection against SARS-CoV-2 clinical outcomes after the second dose of vaccine.

30 Jan, 2022 | 14:51h | UTC

Persistence of protection against SARS-CoV-2 clinical outcomes up to 9 months since vaccine completion: a retrospective observational analysis in Lombardy, Italy – The Lancet Infectious Diseases

Commentary: COVID-19 vaccine: what are we doing and what should we do? – The Lancet Infectious Diseases

FDA halts use of antibody drugs that don’t work vs. Omicron.

30 Jan, 2022 | 14:35h | UTC

FDA halts use of antibody drugs that don’t work vs. omicron – Associated Press

RCT: Vitamin D supplementation for older adults (mean age 67 years) for 5 years reduced the risk of autoimmune diseases by 22%. Absolute risk in the treatment group was 0.95% vs. 1.19% in the placebo group.

30 Jan, 2022 | 14:30h | UTC

Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial – The BMJ

Commentary: Vitamin D and fish oil supplements may help prevent autoimmune disease, study says – CNN

RCT: Oral Vitamin D supplementation (60.000 IU per month) did not reduce mortality in patients 60 years or older (unscreened individuals in Australia, many without insufficiency, average 30ng/mL). Exploratory analyses pointed towards an increased risk of death from cancer.

RCT: Vitamin D supplementation is not beneficial for the prevention of cardiovascular disease and cancer.

USPSTF Draft Statement: Insufficient evidence to recommend multivitamin supplements for the prevention of CVD or cancer. The statement also recommends against the use of beta-carotene (increases risk of CVD mortality and lung cancer) or vitamin E (clear evidence of no benefit)

USPSTF Statement: Insufficient evidence to recommend Vitamin D deficiency screening

Vitamin D, calcium, other vitamins, and supplements do not prevent cardiovascular diseases

Myocarditis after BNT162b2 vaccination in Israeli adolescents.

30 Jan, 2022 | 14:34h | UTC

Myocarditis after BNT162b2 Vaccination in Israeli Adolescents – New England Journal of Medicine

Myocarditis cases reported after mRNA-Based COVID-19 vaccination in the US from December 2020 to August 2021.

A case-control study showed an increased risk of myocarditis after COVID-19 vaccination with a messenger RNA vaccine compared to an inactivated virus vaccine.

[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination vs. SARS-CoV-2 infection.

Case series with 139 adolescents and young adults with suspected myocarditis following mRNA vaccination showed most cases had a mild clinical course and rapid resolution of symptoms.

Heart-inflammation risk from Pfizer COVID vaccine is very low.

Large cohort study with over 2.5 million individuals showed the incidence of myocarditis after the Pfizer vaccine was 2.13 cases per 100,000 persons.

Study with over 5.1 million vaccinated individuals showed the incidence of myocarditis after the receipt of the Pfizer vaccine was low and more common after the second dose in young male recipients.

Large Observational study shows Pfizer Covid vaccine is mostly safe but is associated with increased risk of myocarditis, adenopathy, appendicitis, and herpes zoster.

Commentary on Twitter

Data from the Israeli MOH show estimates of myocarditis risk in the 21 days after a first & second dose of vaccine were 0.56 per 100,000 and 8.09 per 100,000 among male recipients and 0 per 100,000 and 0.69 per 100,000 among females. https://t.co/M6kxVA2toS pic.twitter.com/bQ4TBmcrj4

— NEJM (@NEJM) January 29, 2022

RCT: Olanzapine may improve the control of vomiting in the delayed phase in children receiving highly emetogenic chemotherapy.

30 Jan, 2022 | 14:13h | UTC

Efficacy and Safety of Olanzapine in Children Receiving Highly Emetogenic Chemotherapy: A Randomized, Double-blind Placebo-controlled Phase 3 Trial – Journal of Pediatric Hematology/Oncology (link to abstract – $ for full-text)

Guideline Summary: Management of the top 10 most common immune-related adverse events in patients treated with immune checkpoint inhibitor therapy.

30 Jan, 2022 | 14:11h | UTC

Management of the Top 10 Most Common Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy – JCO Oncology Practice

Original Article: ASCO Guideline Update: Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy.

Clinical practice guideline on immune checkpoint inhibitor-related adverse events.

NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities (several resources on the subject)

M-A: SGLT-2 inhibitors and cardiovascular outcomes in patients with and without a history of heart failure.

30 Jan, 2022 | 13:56h | UTC

SGLT-2 inhibitors and cardiovascular outcomes in patients with and without a history of heart failure: a systematic review and meta-analysis – European Heart Journal – Cardiovascular Pharmacotherapy

Commentary on Twitter

SGLT-2 inhibitors improve CV outcomes irrespective of heart failure history and LVEF: a meta-analysis of RCTs https://t.co/QPRCzT9olH #EHJPharmacotherapy #cardiotwitter @AgewallStefan @GianluSava pic.twitter.com/sESFn7Fdxg

— European Society of Cardiology Journals (@ESC_Journals) January 29, 2022

RCT: Axicabtagene Ciloleucel as second-line therapy for Large B-Cell Lymphoma.

30 Jan, 2022 | 13:41h | UTC

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma – New England Journal of Medicine

Commentary: ZUMA-7 Primary Analysis: Second-Line Axicabtagene Ciloleucel Quadruples Event-Free Survival in Large B-Cell Lymphoma – The ASCO POST

Commentary on Twitter

In a trial involving patients with relapsed or refractory large B-cell lymphoma, the CAR T-cell therapy axicabtagene ciloleucel led to significantly longer event-free survival than standard salvage chemotherapy. #ASH21 https://t.co/V1WfVJ2k9V pic.twitter.com/ZHUhx8es27

— NEJM (@NEJM) December 11, 2021

RCT: Hyperimmune immunoglobulin did not improve outcomes in hospitalized patients with COVID-19.

28 Jan, 2022 | 08:42h | UTC

Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial – The Lancet

Commentaries:

High-dose immunoglobulins from convalescent donors for patients hospitalised with COVID-19 – The Lancet

Hyperimmune intravenous immunoglobulin does not improve outcomes for adults hospitalized with COVID-19 – NIH News Releases

RCT: Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination.

28 Jan, 2022 | 08:37h | UTC

Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial – Nature Medicine

RCT: Heterologous (Pfizer, J&J, or AstraZeneca) vs. homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil.

Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination – Nature Medicine

WHO issues interim recommendations for heterologous COVID-19 vaccine schedules.

Lab study shows new antiviral pills maintain efficacy against Omicron, but antibody drugs are substantially less effective.

27 Jan, 2022 | 10:03h | UTC

Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant – New England Journal of Medicine

Commentary: Current anti-COVID pills work well against omicron, but antibody drugs are less effective, study finds – University of Wisconsin-Madison

Commentary on Twitter

Investigators assessed the in vitro activities of seven monoclonal antibodies & three antiviral drugs against #COVID19 variants. All antibodies showed no or weak neutralizing activity against omicron; two drugs effective at omicron neutralization. https://t.co/rOZzmtsDZS pic.twitter.com/shfKDW6r5q

— NEJM (@NEJM) January 26, 2022

Italian lab study finds Sputnik V beat Pfizer’s mRNA vaccine against Omicron – yielding higher antibody levels.

27 Jan, 2022 | 09:47h | UTC

Italian Lab Study Finds Sputnik V Beat Pfizer’s mRNA Vaccine Against Omicron – Yielding Higher Antibody Levels – Health Policy Watch

Review | Immune-checkpoint inhibitors: long-term implications of toxicity.

27 Jan, 2022 | 09:39h | UTC

Immune-checkpoint inhibitors: long-term implications of toxicity – Nature Reviews Clinical Oncology (if the link is paywalled, try this one)

Commentary on Twitter

New Review by Douglas Johnson, Caroline Nebhan, Javid Moslehi (@CardioOncology) & Justin Balko now live online: 'Immune-checkpoint inhibitors: long-term implications of toxicity' https://t.co/7ymExYiqEY #ImmunoOnc #medonc pic.twitter.com/m6m92mZwOZ

— NatureRevClinOncol (@NatRevClinOncol) January 26, 2022